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Podocytes play a major role in the initiation and
progression of glomerular diseases and are a target of
both immune-mediated and non-immune-mediated injury.
To establish a mouse model of such injury, we preimmunized
mice with Freunds adjuvant 5 days before intravenous
injection of a rabbit polyclonal antibody directed against a
murine podocyte cell line. For the next 7 weeks, we collected
urine, serum, and kidney samples. Nephritic animals
developed severe albuminuria, which was maximal on
day 10. Histochemistry revealed diffuse mesangial matrix
expansion. Mouse immunoglobulin G and complement
were detected in a linear pattern along the glomerular
filtration barrier and in the mesangial hinge region.
Complement depletion, however, did not prevent
proteinuria. Glomerular T cells were increased, whereas
podocytes were significantly reduced. Glomerular foot
processes were flattened in regions with mesangial matrix
deposition as viewed by electron microscopy.
Immunohistochemistry detected the injected anti-podocyte
antibody exclusively at the glomerular tuft on all days
examined. Immunoelectron microscopy localized the
antibody to podocyte foot processes and the glomerular
basement membrane, which was morphologically intact.
This suggests that the podocyte was the main target
of the antiserum. Our study establishes a new mouse
model of immune-mediated podocyte injury.
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The glomerular filtration barrier consists of capillary endo-
thelial cells, the glomerular basement membrane (GBM) and
glomerular epithelial cells (podocytes). Podocytes provide the
crucial barrier to urinary protein loss with hundreds of
podocyte foot processes and the interposed slit diaphragm.1
Most proteinuric renal diseases are typically, although not
exclusively, associated with podocyte damage. Disruption of
podocyte morphology in the form of foot process retraction
(effacement) or slit diaphragm reorganization leads to
massive loss of protein into the urine (proteinuria) and
nephrotic syndrome.
The filtration barrier is the target of both immune- and
non-immune-mediated renal disease. Immune-mediated
glomerular disease can originate from immune deposition
in the glomerulus or a specific antibody-antigen-mediated
immune reaction. Immune deposits along the filtration
barrier occur typically in membrano-proliferative glomer-
ulonephritis type 1, post-infectious glomerulonephritis and
immunoglobulin (Ig)A nephropathy presumably without
specific antibody-antigen recognition. Direct antibody-anti-
gen-mediated damage to glomerular structures has been
shown in anti-GBM nephritis, in which antibodies against
collagen type IV of the GBM mediate GBM destruction in
concert with activated T cells.2,3 Direct antibody-mediated
damage of podocytes has been implicated in membranous
glomerulonephritis, although the specific antigens on podo-
cytes have yet to be identified in humans.4–6 In lupus mice7
and in humans with renal lupus,8 anti-DNA autoantibodies
were found to crossreact with podocyte-specific a-actinin
and induce lupus-like glomerular disease with proteinuria in
mice. a-Actinin is a mayor component of podocyte cyto-
skeleton and mutations of a-actinin can cause hereditary
FSGS with nephrotic syndrome. Recent identification of IgM
antibodies directed against actin and ATPase b subunit in the
serum of pediatric FSGS patients provided possible indirect
evidence of antibody-mediated podocyte damage resulting
in FSGS.9 Therefore, anti-podocyte antibodies seem to play a
role in several different human glomerular disease entities.
It will be crucial to identify the exact antigens responsible
for these proteinuric kidney diseases. Recent discovery of
novel podocyte-specific proteins and their mutation
analysis, including CD2AP, a-actinin-4, podocin, and
neph1, have shown that a multitude of targets exist on the
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podocyte that may act as antigens in immune-mediated
glomerular disease.10–12
Several mouse model systems, which target podocytes
selectively, have been developed recently. In mice expressing
Thy 1.1 exclusively in podocytes, anti-Thy 1.1 antibody
treatment induced immediate proteinuria and podocyte
loss.13,14 Similarly, mice expressing diphtheria toxin receptor
or CD25 on podocytes showed dose-dependent podocyte
damage and proteinuria when treated with diphtheria toxin
or immunotoxin to CD25, respectively.14,15 However, these
model systems used genetically altered mice and induced
rapid destruction of most podocytes. Other model systems
used antibodies targeting-specific proteins on the
podocyte membrane, such as aminopeptidase A,16,17 or the
slit diaphragm protein nephrin18,19 inducing proteinuria with
podocyte foot process effacement. However, we were seeking
to develop an immune-mediated model system of proteinuric
glomerular disease in mice that would allow the identifica-
tion of new antigen targets on the podocyte. Here, we present
the first mouse model of polyclonal antibody-induced
damage to the podocyte.
RESULTS
Proteinuria was induced on day 7 with a maximum on
day 10 after anti-podocyte antibody injection
Urine of antibody-treated and control C57BL/N6 mice was
examined for proteinuria on sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) gels on days 2, 5,
7, 10, and 15 after injection of the anti-podocyte antibody.
All mice injected with anti-podocyte antibody developed
proteinuria after day 5 with maximal proteinuria on day 10
(Figure 1b). In urine of later time points, protein content in
the urine decreased in most mice. However, even on day 49
after injection, severe proteinuria was detected by urine
dipstick in most mice (not shown). Three other mouse
strains were also tested for the ability of anti-podocyte serum
to induce proteinuria. Interestingly, BALB/c and 129S2/Sv
mice showed even increased response to anti-podocyte
serum, whereas DBA/2 mice were more resistant (Table 1).
Albumin was the predominant protein lost to the urine.
Western blots of mouse urine detected albumin at 68 kDa in
similar abundance as on SDS-PAGE gels (Figure 1b, right
panel, alb). Larger proteins typical for unspecific proteinuria
were detected only in small amounts. Specifically, IgG
was found only in grossly proteinuric samples and there in
low abundance (Figure 1b, IgG), suggesting mostly specific
albuminuria. The urine was also tested for podocyte-specific
protein content. Interestingly, Western blots with a mono-
clonal antipodocalyxin antibody detected two bands at
approximately 48 and 29 kDa in antibody-treated mice
(Figure 1b, pdx), but not full-length podocalyxin at
approximately 140 kDa, indicating possible podocyte damage
and cleavage of the podocalyxin protein or its sialic acid
residues. Another podocyte protein, podocin, was also
detected in the urine of proteinuric mice (Figure 1b, pod),
indicating podocyte damage within the glomerulus.
Albuminuria was further quantified using an enzyme-
linked immunosorbent assay (ELISA) for mouse albumin
(Figure 1c). At baseline (5 days after pre-immunization) and
5 days after treatment with anti-podocyte antibodies, urine
albumin content was similar in control (n¼ 4) and treated
animals (n¼ 4). On day 7, a small but nonsignificant increase
in urine albumin was observed in antibody-treated mice.
However, at day 10, nephritic animals had significant
albuminuria with a maximum of 3642760 mg albumin/mg
urine creatinine when compared with control mice
treated with pre-immune serum (13976 mg). Thereafter,
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Figure 1 | Time course, proteinuria, and serum urea nitrogen
in anti-podocyte antibody treated mice. (a) Time course of
pre-immunization and antibody injection in C57 black mice. Asterisks
indicate days on which specimens for urine, mRNA, histology, and
electron microscopy were taken. (b) Left panel: SDS-PAGE separated
urinary protein (5 ml) stained with GelCode. Urine was collected on
the indicated days after antibody application (Ab) or pre-immune
serum application (co). Right panel: Western blots of urine from day
15 probed for albumin (alb), mouse IgG (IgG), podocalyxin (pdx),
and podocin (pod). (c) Quantitation of albuminuria in anti-podocyte
antibody-treated (solid triangles) and control animals (solid squares)
at the indicated time points, n¼ 4 for each condition. Albumin ELISA
results were normalized for urine creatinine. (d) Mean values of serum
urea nitrogen (n¼ 3–5) at the indicated time points. Asterisks indicate
significant albuminuria or serum urea nitrogen in anti-podocyte
antibody-treated mice compared with control on the same day.
Table 1 | Proteinuria in four different mouse strains 10 days
after anti-podocyte serum application (male mice, n=5 for
each group, scale 0-++++)
Mouse strain C57BL/6N 129S2/Sv BALB/c DBA/2
Proteinuria ++ +++ ++++ +
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albuminuria decreased to 28697629 mg albumin/mg urine
creatinine on day 15.
Serum urea nitrogen was significantly elevated in
antibody-treated mice
Serum creatinine and serum urea nitrogen were measured in
three mice per time point on days 0, 2, 5, 10, and 15 (Figure
1d). Serum urea nitrogen was significantly elevated on days 5
and 10 (max. 105.2720.3 mg/dl) in antibody-treated
mice compared with control mice (max. 52.576.7 mg/dl).
No significant differences were found in serum creatinine
values. Serum creatinine was 0.0870.014 g/l in control and
0.0970.015 g/l in antibody-treated mice. In addition, mice
body weights were determined throughout the course
of the experiment to detect possible weight gain due to
hypo-oncotic edema. However, total body weight was not
significantly different (25.370.7 and 26.170.8 g) in control
and antibody-treated mice, respectively.
Rabbit polyclonal anti-podocyte antibodies bound specifi-
cally to in vitro cultured podocytes by immunohistochemistry
The rabbit anti-mouse podocyte polyclonal antibody was
evaluated by immunofluorescence on cultured differentiated
podocytes. Specific staining of podocyte structures was
detected along the foot processes with predominant staining
of the tips (Figure 2a) when compared with control (panel b).
In addition, specific staining was present at the leading edges
of membrane protrusions in each cell. Additionally, peri-
nuclear cytoplasmatic staining was apparent in methanol
fixed podocytes but less prominent after paraformaldehyde
fixation. Cell membranes, nucleus, and peripheral cytoplasm
displayed only weak antibody binding. In contrast, specific
binding to mesangial cells in culture was not detectable after
incubation with anti-podocyte serum (Figure 2c) or pre-
immune serum (panel d).
Rabbit polyclonal anti-podocyte antibodies bind to the
glomerular tuft in paraffin-embedded mouse kidney
Immunohistochemistry of paraffin-embedded naı¨ve mouse
and rat kidneys was performed to detect native structures in
the kidney recognized by the antibody. In mice, the anti-
podocyte antibody exhibited strong binding to the glomer-
ular filtration barrier and along the outer aspect of the
glomerular tuft consistent with binding to podocytes (Figure
2e) when compared with control (panel f). Additional
staining was detected in the cytoplasm of proximal tubular
cells within Bowman’s capsule and weakly along the
basement membrane of these cells. In rat kidneys, strong
staining of the glomerular filtration barrier without tubular
or basal membrane staining was observed (data not shown).
In vivo, anti-podocyte antibodies bound exclusively to the
glomerular filtration barrier in a linear pattern
In contrast to the broader binding pattern of anti-podocyte
antibody on naı¨ve mouse kidneys in vitro, the in vivo binding
pattern of anti-podocyte antibody after intravenous (i.v.)
injection was highly specific at all days examined (Figure 3a,
c, e, and g). Staining of mouse kidney sections with
affinity purified Cy2 anti-rabbit IgG detected the injected
anti-podocyte antibody only in glomeruli along the GBM in a
linear pattern. No cytosolic staining of glomerular or tubular
cells or staining of the basal membrane of Bowman’s capsule
or tubuli as in the naı¨ve kidney was present. Control mice,
which were i.v. injected with rabbit pre-immune serum,
showed no specific immunoreactivity to Cy2 anti-rabbit IgG
in the kidneys (Figure 3b, d, f, and h).
Histological changes in antibody-treated mice
Mice were killed on day 1, 2, 5, 7, 10, 17, and 49
following administration of the anti-podocyte antibody or
pre-immune serum and kidneys were evaluated by histology
(Periodic Acid Schiff, PAS) and immunohistochemistry.
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Figure 2 | Antibody-binding pattern to podocytes and mesangial
cells in culture or naı¨ve mouse kidney. Immunofluorescence of
differentiated podocytes (a and b) or mesangial cells (c and d) in
culture stained with rabbit anti-podocyte antibody (a and c) or rabbit
pre-immune serum (b and d). Arrows in (a) indicate predominant
staining of the antibody in areas of foot process formation. Naı¨ve
mouse kidney sections were stained with (e) anti-podocyte antibody
or (f) pre-immune serum. All samples were visualized with Cy2-
coupled secondary anti-rabbit antibody. The double arrow in (c)
indicates discrete staining of the basal membrane of proximal tubular
cells along Bowman’s capsule. White arrows indicate staining along
the GBM.
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Predominantly, glomerular disease was observed in anti-
podocyte antibody-treated mice (Figure 4a) but not in
control mice treated with the same amount of pre-immune
serum (Figure 4b). In all mice, glomerular pathology was
found in a diffuse distribution with 490% of the glomeruli
affected and only few glomeruli of normal appearance. The
number of cells in typical podocyte locations appeared
reduced. An expansion of PAS-positive mesangial matrix
without mesangial hypercellularity was observed. Capillary
diameters were normal. In highly proteinuric mice, some
tubuli were obstructed by proteinaceous casts. Within the
obstructed tubuli, tubular epithelial cells were swollen
and vacuolated possibly reflecting endocytosis of protein.
Inflammatory cell infiltrates were present in the periglo-
merular and peritubular space and, to a lesser extent, within
the glomerulus.
IgG- and C3- but not IgM-deposits in glomeruli
of antibody-treated mice
Immunological analysis of anti-podocyte antibody-treated
mice demonstrated glomerular mouse IgG deposition in a
linear pattern together with IgG clusters within the
mesangium (Figure 4c), whereas mice injected with pre-
immune serum showed minimal IgG reactivity (Figure 4d).
Similarly, immunohistological analysis of complement C3
showed similar linear and cluster-like glomerular deposition
(Figure 4e) with minimal amounts in control animals
(Figure 4f). Mouse IgM or mouse IgA was not detected in
anti-podocyte antibody or pre-immune serum-treated
control mice (not shown).
Fibrosis or sclerosis was not detected in glomeruli
of antibody-treated mice
To examine the origin of PAS-positive mesangial deposits in
antibody-treated mice, collagen type IV and smooth muscle
actin staining were performed as markers for glomerular
sclerosis. Forty-nine days after antibody treatment, no
accumulation of collagen type IV staining or smooth muscle
actin was detected within the glomerular tuft in antibody-
treated mice (Figure 4g) when compared with control mice
(Figure 4h).
Podocyte foot process effacement in areas of mesangial
deposits
Transmission electron microscopy of proteinuric mice
revealed segmental foot process effacement (Figure 4i).
Podocytes revealed a swollen cytoplasm and open chromatin.
There was an increase in pinocytotic vesicles in the podocyte
foot processes (Figure 4j). The GBM was well preserved
throughout the observation period including, 49 days after
antibody application. Only very small electron dense deposits
in the lamina rara externa were visible. Similar deposits were
present in the mesangial hinge region (Figure 4k). The
overlying foot processes on some of these deposits were
effaced. Endothelial cells and all other portions of the
glomerulus were unremarkable.
Podocin and anti-podocyte antibody staining patterns
colocalized along the glomerular filtration barrier
Immunofluorescence of the podocyte-specific protein
podocin showed a linear staining pattern along the GBM in
antibody-treated (Figure 5b) and control mice. Podocin
colocalized with anti-podocyte antibody (Figure 5a) by
confocal computational analysis (Figure 5c). However,
higher resolution revealed that podocin and anti-podocyte
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Figure 3 | Antibody-binding pattern in mice in vivo.
Immunofluorescence of representative mouse kidney sections of
mice treated with anti-podocyte antibody (a, c, e, g) or pre-immune
serum (b, d, f, h) on the indicated days. In vivo anti-podocyte
antibody binding was visualized with Cy2-coupled secondary anti-
rabbit antibody. Note, that basal membranes of Bowman’s capsule
were not stained in anti-podocyte antibody-treated animals at all
times. (b) Discrete staining was visible in day 1 pre-immune serum
controls.
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antibodies were not completely congruent (Figure 5d–g).
Some rabbit IgG-positive areas were surrounded by
podocin staining and presumably corresponded to the
GBM (Figure 5g).
Immunogold electron microscopy detected anti-podocyte
antibody on podocyte foot processes and along the GBM
By immunogold labelling, rabbit IgG was detected along the
cell membrane of podocyte foot processes and in all layers of
the GBM on day 1 (Figure 5h) and day 8 (panel i).
Endothelial cells, mesangial cells, mesangial matrix, cell
bodies, and more proximal processes of podocytes, tubular
epithelial cells, and all other cortical basement membranes
were negative.
The number of podocytes per glomerular area was reduced
in treated mice
PAS staining suggested a reduced number of podocytes in
anti-podocyte antibody-treated mice and electron micro-
scopy revealed podocyte damage in some areas of the
glomerulus. Therefore, the number of podocytes per
glomerular area was determined (Figure 6). The glomerular
area was measured in a semi-automated system, which
allowed the calculation of a mean glomerular area in 50
systematically screened glomeruli per section. Podocyte
nuclei were stained with the podocyte-specific marker
WT-1 and counted manually in 50 glomeruli per section.
Quantification of podocyte number per glomerular area
revealed a significant decrease in podocyte density in
antibody-treated mice compared with control mice
(Figure 6(a–c)). Glomerular volume, which was calculated
from mean glomerular area according to Weibel,20 was
not different between antibody-treated and control mice
(Figure 6g). Together, these data suggest a loss of podocytes
from the glomerular tuft.
The number of T cells increased in glomeruli
of antibody-treated mice
Quantification of CD3-positive T cells was performed by
immunofluorescence (Figure 6f). Sixty glomeruli were
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Figure 4 | Histology, immunohistochemistry, and electron microscopy of anti-podocyte antibody-treated mice. (a–h) PAS staining
of anti-podocyte serum-treated (a) and control (b) mice killed on day 10 after serum application. (c–h) Confocal microscopy of stainings
against (c, d) mouse IgG, (e, f) complement 3, and (g, h) a-smooth muscle actin on day 10 in serum (c, e and g) or control (d, f, h) mice.
(i–k) Representative electron micrographs of anti-podocyte antibody treated mouse glomeruli. (i) overview, original magnification  4 500,
(j) electron dense deposits in the hinge area (white arrows), original magnification  15 000, and (k) pinocytotic vesicles on foot processes,
(black arrows, original magnification  30 000).
Kidney International (2007) 72, 841–852 845
TN Meyer et al.: Anti-podocyte nephritis o r i g i n a l a r t i c l e
systematically screened, CD-3 positive cells were counted
for each glomerulus and the glomerular area was deter-
mined as outlined above. CD3-positive T cells were
significantly increased within the glomeruli of anti-podocyte
antibody-treated mice (0.5570.052) versus control mice
(0.1870.028).
Complement activity was not necessary for anti-podocyte
serum to induce proteinuria
Complement was depleted in mice by repeated cobra venom
factor (CVF) injections before and after application of anti-
podocyte serum or pre-immune serum until proteinuria
developed. Immunostaining for anti-podocyte antibody
showed identical antibody distribution in control (Figure
7a) and complement-depleted (Figure 7b) anti-podocyte
antibody-treated mice. Complement C3 was only minimally
detected in kidneys of complement-depleted animals
(Figure 7d) when compared with control (Figure 7c).
Albuminuria developed along the same time course in
complement-depleted mice compared with controls and
was of comparable amount (Figure 7e). In addition, cell
lysis experiments on podocytes in culture were carried out
with anti-podocyte antibody or pre-immune serum without
or with heat inactivation for complement inactivation
(Figure 7f). However, cell lysis was not significantly
different under complement-inactivated versus complement-
containing conditions.
DISCUSSION
We have investigated the effect of polyclonal rabbit
anti-mouse podocyte antibodies on mice, and show that
antibody-treated mice develop severe proteinuria with linear
deposition of the rabbit antibody, mouse IgG and comple-
ment 3 within the glomerular tuft. This represents the
first mouse model targeting the glomerular podocyte with
antibodies to induce an immune reaction at the podocyte.
Differentiated cultured podocytes were used as antigen
for immunization of rabbits. These cells express several
markers typical for differentiated podocytes in vivo.21 The
obtained polyclonal anti-podocyte antibody showed specific
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Figure 5 | Confocal colocalization of podocin and anti-podocyte antibody and localization of anti-podocyte antibody by
immunogold electron microscopy immunofluorescence. (a) Anti-podocyte antibody and (b) podocin localized along the GBM (combined).
(c) However, higher resolution (d–g) revealed only partial colocalization (g) on the podocyte (nucleus (f, ToPro3), marked with an asterisk)
of anti-podocyte antibody (d, Cy3), podocin (e, Cy2). Immunogold electron microscopy of representative sections from anti-podocyte-treated
mice day 1 (h, original magnification  52 000) and day 8 (i, original magnification  70 000). Black arrows indicate gold particles (10 nm)
along the GBM and double arrows indicate gold particles along the cell membranes of foot processes.
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immunofluorescent staining on podocyte foot processes as
well as in the cytosol on podocytes in culture. A crossreaction
of the antibody with nonspecific podocyte proteins that are
also expressed in other cell types could have been expected
after i.v. application into the tail vein of mice. To our
surprise, only the glomerulus showed a specific reaction and
within the glomerulus, only the GBM and the adjacent foot
processes were positive for rabbit IgG by immunogold
electron microscopy. Endothelial cells or the mesangium
were negative. The binding pattern in the GBM was
suggestive of anti-GBM nephritis. Two mouse models of
anti-GBM nephritis, the autoimmune anti-GBM disease
(experimental autoimmune glomerulonephritis (EAG), using
recombinant human alpha3(IV)NC1 as antigen) and the
nephrotoxic serum nephritis model Nephrotoxic Serum
Nephritis (NTS), using anti-glomerular serum, are currently
used. Both lead to an exclusively linear immunohistochemi-
cal IgG deposit comparable with the findings in our
model.22–24 However, in both experimental settings, comple-
ment-dependent destruction of the GBM can be detected
within a few days and crescents are present in approximately
one-third of the glomeruli.25,26 Furthermore, peritubular
endothelial disruption is typically detected together with
infiltrating pericapillary macrophages. In our model, the
GBM appeared normal on all electron micrographs studied
throughout the time course and crescents did not form in any
mouse, although proteinuria persisted for 49 days. No
endothelial damage was detected by light or electron
microscopy and complement was not necessary for anti-
podocyte serum activity. Therefore, our new model shows
some overlapping features with nephrotoxic serum nephritis
but also clearly podocyte-specific damage.
What is the most likely pathogenesis in our model? The
onset of proteinuria was not immediate, but occurred after
7 days with maximal proteinuria around day 10 after
application of the antibody. Furthermore, proteinuria
occurred only after pre-immunization with Freund’s adju-
vant. In preliminary experiments, direct i.v. application of the
podocyte antibody in non-pre-immunized mice did not
induce proteinuria within 20 days. It is unlikely that the
observed time lag can be explained by difficulties of the
antibody to reach the antigen at or beyond the GBM. In other
model systems with antibody application to mice using anti-
aminopeptidase A or anti-nephrin antibodies, immediate
immune responses and proteinuria were observed without
pre-immunization.16,18 Antibody application in mouse
Thy-1.1 nephritis initiated proteinuria within 10 min, with
a maximum after 5 h and normal urine after 7 days.13 In our
mice, the rabbit antibody was present on the podocyte
and in the GBM 24 h after anti-podocyte antibody injection.
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Figure 6 | Podocyte and CD3 cell count in control and anti-podocyte antibody-treated mice. (a–c) Quantitation of podocyte number per
mean glomerular cross-sectional area of 50 systematically sampled glomeruli in PAS staining of control (Co, white bar) and anti-podocyte
antibody-treated (Ab, black bar) mice on day 10. Right panel: immunohistochemistry for WT1-positive podocytes in glomeruli of (b) control and
(c) anti-podocyte serum-treated mice. White arrows indicate a segmental loss of WT1-positive cells. (d–f) Quantitation of CD3-positive
T-cells per glomerular area under both experimental conditions. Right panel: immunohistochemistry for CD3-positive T-cells in glomeruli of
(e) control and (f) anti-podocyte serum-treated mice. Black arrows indicate CD3-positive cells in glomeruli and interstitium. (g) Quantitation
of glomerular volume as detailed in Materials and methods. Asterisks indicate statistical significance, n.s. indicates no significant difference
between control (Co, white bar) and antibody-treated (Ab, black bar) animals, (n¼ 4 each).
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Therefore, podocyte damage most likely involved a secondary
immune response in our model. Secondary immune
responses are typical for many glomerulonephritis settings.
Antibody binding or deposition triggers an inflammatory
reaction in the glomerulus associated with complement
activation and/or FcgR pathways.27,28 Subsequent T-cell-
mediated cellular immunity has long been suspected as
potentially the most important mediator of glomerulone-
phritis.29 T cells may participate as helper cells in
T-dependent antibody response to renal autoantigens.
Autoantibodies associated with human disease, such as
anti-GBM antibodies, can initiate a T-cell-dependent re-
sponse.3 In our model, T-cell number was increased within
the glomerulus during the proteinuric phase. Hence, T-cell
activation could partially mediate podocyte damage in this
model setting. In addition to increased T-cell number,
periglomerular polymorphonuclear cell infiltrates were
noted. Periglomerular infiltrates occur in autoantibody-
mediated diseases, such as systemic lupus erythematodes,
and in experimental intra-glomerular nephritis, such as
rat Thy 1.1. nephritis,30 and passive Heymann Nephritis, but
their contribution to glomerular or podocyte damage
remains unclear. Recently, it has been suggested that dendritic
cells can act as a mediator from kidney to lymph node, where
T cells are primed to shuttle back into the kidney via the
blood stream.31 In summary, a T-cell-mediated secondary
immune response in the glomerulus is likely to have
contributed to proteinuria. A further evaluation of the
invading inflammatory cells is currently under way.
Proteinuria followed an early rise in serum urea nitrogen
indicating acute renal failure and was not due to protein
overload. Control mice that were injected with the same
amount of pre-immune rabbit serum did not develop
proteinuria. Albumin was the predominant protein fraction
in the urine indicating specific damage of the slit diaphragm
of podocyte foot processes. Podocalyxin break down
products were found in proteinuric urine also indicating
podocyte damage, although the relevance of podocalyxin in
the urine is not clear and podocalyxin may originate from
other cells than the glomerular podocyte.32,33 Nevertheless,
urine from massively proteinuric mice also contained IgG
and podocin, suggesting podocyte loss in some areas.
Consistent with this finding, the number of podocytes per
glomerulus was significantly reduced in anti-podocyte anti-
body-treated mice. In addition, scanning electron microscopy
showed flattened foot processes in a segmental distribution
within the glomerular tuft and podocytes showed increased
pinocytotic activity consistent with proteinuria. These data
suggested that the podocyte foot process was the main target
of the anti-podocyte antibody causing proteinuria. However,
the specific antigen(s) recognized by the antibodies remain
unknown. Whereas a multitude of recently discovered
podocyte-specific proteins, such as CD2AP, a-actinin-4, and
neph1, could be the antigenic target of this serum,10–12
virtually any other cytosolic, nuclear, or membrane-bound
protein could be a major antigen in this setting. We are
currently investigating the antigens presented by cultured
podocytes that may be responsible for the observed
phenotype by mass spectrometry. Preliminary results did
not identify any known podocyte-specific proteins.
Glomerular mesangial matrix expansion was noted in
anti-podocyte antibody-treated mice suggesting a mesangial
target of the antibody. This mesangial expansion was
not caused by increased sclerotic activity in our model.
Immunohistochemistry did not detect increased amount of
collagen and smooth muscle actin as markers for increased
fibrosis in glomeruli from proteinuric mice throughout the
study period. Both proteins are commonly upregulated 10–14
days after fibrotic stimuli as in unilateral ureteral obstruction
mice.34 In rat Thy 1.1 nephritis, typical mesangial scarring
occurs within 7 days after mesangiolysis.35 Mesangiolysis or
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Figure 7 | Complement depletion in anti-podocyte serum-treated
mice and podocyte viability assay. (a–d) Immunohistochemistry of
rabbit IgG (a, b) and complement 3 (c, d) on day 10 in anti-podocyte
serum-treated mice (250ml, a, c) or mice that were additionally
complement depleted (b, d). For complement depletion, CVF was
injected (4U i.p.) every 2 days beginning 3 days before application of
the anti-podocyte serum. (e) SDS-PAGE of urine from pre-immune
serum-injected (pre-imm.), anti-podocyte serum-injected (APN), or
additionally complement-depleted mice (APNþCVF). (f) Trypan blue
exclusion assay of podocyte viability after addition of pre-immune
serum (left columns, pre-imm.) or anti-podocyte serum (right
columns, APN) to differentiated podocytes in culture. In some
experiments, anti-podocyte serum was heat inactivated (lane 2 and 4)
to deplete complement activity (n¼ 5 for each condition).
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mesangial hypercellularity were not detected in our model.
Furthermore, mesangial binding or mesangial deposition
of the anti-podocyte antibody following i.v. injection was
not detectable in immunofluorescence or immuno-electron
micrographs on day 1 or 8. On electron micrographs,
mesangial cells appeared healthy. Instead, the mesangium
contained small electron dense deposits in the hinge region.
By immunofluorescence, these deposits most likely contained
mouse IgG and complement. Podocyte foot process efface-
ment occurred predominantly in areas with deposits,
suggesting immune deposits contributing to podocyte
damage.
In summary, this new model of anti-podocyte antibody-
induced heavy proteinuria in mice and is characterized by
immune-mediated podocyte loss, foot process effacement,
and complement activation. The exact mechanisms of
podocyte injury remain to be determined. We propose to
name the new model anti-podocyte nephritis (APN).
MATERIALS AND METHODS
Generation of rabbit polyclonal antibodies against mouse
podocytes
Podocyte cell culture. Murine podocytes (kindly provided by
Peter Mundel21,36 were cultured under permissive (331C, 5% CO2,
RPMI 1640 supplemented with 10% fetal calf serum, 10 mmol/l
N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid, 1 mmol/l so-
diumpyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin, 10 U/
ml interferon-g (PeproTech, London, UK)) as described. For
differentiation, podocytes were cultured for 14 days under non-
permissive conditions (371C, 7.4% CO2, RPMI 1640 supplemented
with 10% fetal calf serum, 10 mmol/l N-2-hydroxyethylpiperazine-
N0-2-ethanesulfonic acid, 1 mmol/l sodiumpyruvate, 100 U/ml
penicillin, 100 mg/ml streptomycin). Cell density was kept below
90% to allow foot process development.
Rabbit immunization and polyclonal antibody concentration
Before immunization, rabbits were bled from the ear vein to obtain
pre-immune serum for control experiments. The immunization
schedule comprised a primary subcutaneous immunization with
500ml of podocyte cell suspension (approximately 5 109 cells) in
500ml TiterMax Gold Adjuvant (Sigma, Steinheim, Germany),
followed by four monthly boost immunizations of podocytes
emulsified in TiterMax and serum titer assessments. Podocyte-
specific antibody titers of the serum were detected using an ELISA
developed in our laboratory. In brief, differentiated cultured
podocytes were covalently fixed to the ELISA plate and used as
antigen in serial dilution experiments. One week after the final
boost, rabbit serum was collected. Following removal of the blood
clot, rabbit anti-podocyte serum was centrifuged at 2500 U/min for
20 min. Serum was complement inactivated by heating (30 min at
561C in a water bath) and concentrated twofold by high-pressure
membrane filtration technique (Amicon stirred cell 8000 series,
Millipore, Eschborn, Germany).
Characterization of rabbit polyclonal antibody against mouse
podocytes or mouse mesangial cells
Murine mesangial cells were a kind gift from Ulrike Hopfer. Cells
were cultured at 371C in 5% CO2 and were grown in Dulbecco’s
modified Eagle’s medium (Gibco-BRL, Eggenstein, Germany)
containing 100 mg/dl D-glucose (G100) supplemented with 10%
fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, and
2 mmol/l glutamine. Cells were passaged every 5 days.
Generated antibodies were tested by immunofluorescence on
differentiated podocytes and mesangial cells cultured on glass
coverslips and by immunohistochemistry on frozen or paraffin-
embedded mouse and rat kidney sections (see below). Cells were
fixed with either 2% paraformaldehyde in 4% sucrose for 8 min or
with 100% ice-cold methanol for 5 min. Specific binding of anti-
podocyte serum to the cells was assessed by indirect immunofluor-
escence. Briefly, anti-podocyte serum was diluted 1:100–1:500 in 5%
horse serum (Vector, Burlingame, CA, USA) and incubated for 1 h at
room temperature. Binding was visualized using an affinity purified
Cy2 donkey anti-rabbit antibody (Jackson Immunoresearch
Laboratories, Soham, UK) diluted 1:200 in 5% horse serum for
30 min. Stainings were evaluated with a confocal microscope (LSM
510, Zeiss, Oberkochen, Germany) using the LSM software.
Murine model of APN
Animal care. Mice were housed in a controlled animal facility with
free access to water and standard animal chow. The animal
experiments were performed according to national and institutional
animal care and ethical guidelines and have been approved by the
committees.
Immunization time course. In 14 separate experiments with
n¼ 3–5 for each condition and time point, male C57BL/6N mice
(25–30 g body weight, 12–14 weeks old, Charles River Wiga, Sulzfeld,
Germany) were preimmunized subcutaneously with 250ml rabbit Ig
(Sigma) in 250ml Freund’s adjuvant (Sigma). Five days later, mice
were given 500ml rabbit anti-podocyte serum per i.v. injection into
the tail vein. Control mice were given 500 ml of concentrated rabbit
pre-immune serum. Urine was evaluated for proteinuria on days 1,
2, 5, 7,10, 15, 17, and 49. Mice were weighed and killed at days 1–49
by cervical neck dislocation. Following the collection of blood,
kidneys were perfused through the aorta with phosphate-buffered
saline. Kidneys were cut into equal pieces for the isolation of mRNA
and protein, for histology and electron microscopy. Serum
creatinine and serum urea were determined by standard methods
in the department of clinical chemistry at the university hospital. In
three additional experiments, three different mouse strains (129S2/
Sv, BALB/c, DBA/2) were challenged with anti-podocyte serum
according to the protocol above and proteinuria on day 10 was
visualized by SDS-PAGE (males, n¼ 5 for each group).
Complement depletion. CVF (Quidel Corp., Osteomedical,
Buende, Germany) was used for depletion of complement of mice in
accordance with the German animal protection act and after consent
(82/06) by the local government. Three experiments were performed
with decomplementation protocols as described previously.37 This
treatment decreased serum C3 levels to 10% of normal values.38 In
addition to the control and anti-podocyte serum groups, two
additional groups of 10 mice received CVF alone or CVF plus anti-
podocyte serum. CVF (4 U) were administered i.p. 3 days and 1 day
before the injection of anti-podocyte serum and on days 1, 3, 5, 7,
and 9 after the injection. To avoid acute reactions to anti-podocyte
serum, the amount of injected serum had to be halved.
Trypan blue exclusion assay
Podocytes were treated with 10% anti-podocyte serum or pre-
immune serum or with heat inactivated (complement depleted,
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30 min 561C) anti-podocyte serum or pre-immune serum for
30 min. Cells were washed with phosphate-buffered saline twice,
trypsinized, and exposed to 0.4% trypan blue in phosphate-buffered
saline for 5 min. Viable and trypan blue positive, non-viable cells
were detected in a Neubauer-counting chamber.
Analysis of proteinuria
Proteinuria was assessed by SDS-PAGE of mouse urine collected
over 6–8 h in 96-well plates. Total urine volume was not measured.
Urine (5 ml) were loaded in 4 LDS (lithium dodecyl sulfate)
sample buffer onto a 4–12% graded Bis-Tris NuPage Gel (Invitrogen,
Karlsruhe, Germany) and run in 50 mM 3-[N-morpholino]propane
sulfonic acid buffer for 1 h at 60 mA. Following electrophoretical
separation, proteins were visualized by GelCodes (Pierce,
Bonn, Germany) according to the manufacturers’ instructions and
scanned.
For immunoblotting of mouse albumin (1:15 000, Bethyl,
Montgomery, TX), mouse IgG (1:15 000, Jackson Immunoresearch
Laboratories, Hamburg, Germany), podocalyxin (1:20 000, rat mAb,
R&D Systems, Wiesbaden, Germany), and podocin (1:20 000, Santa
Cruz, goat pAb (G-20), La Jolla, CA), urine was centrifuged for
5 min at 1000 g and denatured as mentioned. Urine samples were
separated on a 4–12% Bis-Tris NuPage gel (Invitrogen) in 50 mM
3-[N-morpholino]propane sulfonic acid buffer for 1 h at 60 mA.
Protein transfer to an activated polyvinylidine difluoride membrane
(Millipore) was performed in transfer buffer (25 mM Tris base,
0.192 M glycine, 20% methanol in ddH2O) in a Novex Mini Cell
(Invitrogen) for 1.5 h at 30 V and 41C. The polyvinylidine difluoride
membranes were blocked in 5% NFM (non fat milk) for 60 min
before incubation with primary antibodies diluted in Superblock
blocking reagent (Pierce). The primary antibody was removed by
washing in Tris-buffered saline with 0.1% Tween for 40 min and
detected by incubation for 45 min with horseradish peroxidase-
coupled secondary antibodies (all Jackson Immunoresearch Labora-
tories, Hamburg, Germany) diluted 1:15 000 in 5% NFM. After
washing in Tris-buffered saline with 0.1% Tween for 40 min, protein
was visualized with ECL SuperSignal (Pierce) according to the
manufacturer’s instructions on a Biomax Light Film (Kodak,
Rochester, NY, USA).
Albumin ELISA
Urine albumin content was quantified using a commercially
available ELISA system (Bethyl) according to the manufacturer’s
instructions. Briefly, 96-well plates were coated 1:100 with goat anti-
mouse albumin in binding buffer (0.05 M carbonate-bicarbonate pH
9.6) for 60 min at room temperature. After washes in 50 mM Tris,
0.14 M NaCl, 0,05% Tween-20, pH 8,0, the plates were blocked for
30 min at room temperature with 50 mM Tris, 0.14 M NaCl, 1%
bovine serum albumin, pH 8,0 and rewashed. Diluted urine was
incubated for 60 min at room temperature. Following washes, the
secondary antibody (1:20 000, horseradish peroxidase goat anti-
mouse albumin) was applied for 60 min at room temperature. After
washes, enzyme substrate supplied by the kit was added and the
color development was stopped after 20 min with 2 M sulfuric acid.
Extinction was measured at 450 nm in an ELISA plate reader
(BioTek, Winooski, VI, USA, EL 808). The urinary albumin
concentration was calculated according to the formula for
absorption¼ (AD)/1þ (x/C)BþD), where A and D are values
from the standard curve. Regression values for the standard curve
were calculated to assess the accuracy of the measured values.
Standard curves with r-values 40.9950 were used. The urinary
albumin values were standardized against urinary creatinine values
of the same animals.
Immunohistochemistry
Whole kidneys were perfusion- and post-fixed in 4% buffered
formalin for 24 h and embedded in paraffin (Medim Histotechno-
logie, Buseck, Germany). For immunohistochemical stainings, 1 mm
tissue sections were deparaffinized and rehydrated. Antigen retrieval
was performed by incubation with proteinase type XXIV (5 mg/ml,
Sigma, Steinheim, Germany and St Louis, MO, USA) for 15 min at
371C or by microwave antigen retrieval in citrate buffer, pH 6.1 for
25 min. For the staining of frozen sections, 6 mm sections were fixed
in 100% ice-cold acetone and antigen retrieval was omitted. After a
30 min block in 5% horse serum, the tissue was incubated with
rabbit anti-podocyte antibody in several dilutions (1:100–1:5000 in
5% horse serum) for 1 h at room temperature. Binding was visualized
using an affinity purified Cy2 donkey anti-rabbit antibody (Jackson
Immunoresearch Laboratories, Hamburg, Germany) diluted 1:200 in
5% horse serum for 30 min. Other primary antibodies used were goat
anti-C3 (1:200, MP Biomedicals, Solon, OH, USA), rabbit anti-WT-1
(1:500, C-19, Santa Cruz), goat anti-podocin (1:50, Santa Cruz), goat
anti-collagen Type IV (1:400, Southern Biotech, Birmingham, AL)
and biotinylated mouse anti-smooth muscle actin (1:100, Neomar-
kers, Fremont, CA), and rabbit anti-mouse CD3 (1:40, DAKO,
Hamburg, Germany). All secondary antibodies used were biotinylated
or Cy2-conjugated affinity purified donkey antibodies (Jackson
Immunoresearch Laboratories). Biotinylated secondary antibodies
were visualized with the ABC-AP Kit (Vector) according to the
manufacturers instructions followed by Neufuchsin (Merck, Darm-
stadt, Germany) color development for light microscopy or avidin-
fluoresceine isothiocyanate (Vector) for immunofluorescence. ToPro3
(Molecular Probes, Invitrogen, Karlsruhe, Germany) was used for
nuclear staining. Stainings were evaluated under an Axioskop (Zeiss,
Jena, Germany) and photographed with an Axiocam HRc (Zeiss,
Jena) or by confocal microscopy with an LSM 510 beta microscope
using the LSM software.
Electron microscopy
Electron microscopical analysis was performed on whole kidneys
that were perfusion-fixed in 4% buffered paraformaldehyde. Tissue
was post-fixed with 1% osmium in 0.1 M sodium-cacodylat
buffer, stained with 1% uranylacetate and embedded in epoxy-resin
(Serva, Heidelberg, Germany). Ultra thin sections were cut
(ultramicrotome, Reichert-Jung, Nussloch, Germany) and con-
trasted with uranyl acetate in methanol followed by lead citrate.
Micrographs were generated with a transmission-electron micro-
scope (JEM 1010, JEOL)
Immunoelectron microscopy
Cortical tissue was fixed in 4% buffered paraformaldehyde,
dehydrated in graded ethanols and embedded in LR–White resin.
Polymerization was allowed for 24 h at 601C. Ultrathin sections were
steamed for 1 h in citrate buffer at pH 9.0 (DakoCytomation,
Hamburg, Germany). Unspecific binding was blocked with
donkey serum (Jackson Immunoresearch Laboratories, Hamburg,
Germany). Sections were then incubated with 12 nm colloidal gold-
conjugated donkey anti-rabbit IgG (Jackson Immunoresearch,
Hamburg, Germany) overnight at 41C followed by contrasting with
uranyl acetate and lead citrate. Representative micrographs were
taken on a Philips electron microscope (EM201, Philips, Eindhoven,
The Netherlands).
850 Kidney International (2007) 72, 841–852
o r i g i n a l a r t i c l e TN Meyer et al.: Anti-podocyte nephritis
Measurement of glomerular volume and podocyte
and T-cell count
Kidney cortex was embedded in paraffin for light microscopy
examination. Three-micrometer thick sections were cut on a
rotation microtome and stained with periodic acid shift reagent
(Sigma, Steinheim, Germany). The mean glomerular tuft volume
(VG) was determined from the mean glomerular cross-sectional area
(AG) at a magnification of  200, as described previously.20
Planimetric examinations of glomerular cross-sectional area were
performed by means of a Zeiss drawing tube in combination with a
semiautomatic interactive image analysis system (Morphomat;30
Zeiss) as described.39 Using a serpentine movement from cortex to
medulla and vice versa, the outlines of 50 consecutively encountered
capillary tufts were traced manually and the mean glomerular
random cross-sectional area (AG) was determined. The average
glomerular tuft volume VG was calculated as VG¼ b/k (AG)3/2,
where b¼ 1.38, which is the shape coefficient for spheres (the
idealized shape of glomeruli), and k¼ 1.1, which is a size
distribution coefficient.20
For the evaluation of podocyte number per mean glomerular
cross-sectional areas, 3 mm thick paraffin sections were stained for
WT-1. WT-1 antibody stained podocyte nuclei in mouse glomerular
tissue sections. WT-1-positive nuclei were counted in 50 glomeruli
systematically sampled at  200 magnification to allow calculation
of the podocyte nuclei number per mean glomerular cross-
sectional area. For T-cell count, 20 visual fields of the cortical
region of three consecutive sections of n¼ 4 mice for each condition
were evaluated at a magnification of  40. Each visual field
evaluated comprised at least two glomerular cross-sections.
Only T cells within Bowman’s capsule and the glomerular tuft were
counted as glomerular T cells. Statistical analysis was performed
using the unpaired t-test. A Pp0.05 was considered statistically
significant.
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